LPCAT1

Across TCGA pan-cancer cohorts, LPCAT1 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of LPCAT1’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where LPCAT1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types LPCAT1 is over-expressed in tumor, although a few such as LSCC show the opposite, repressed pattern.

CCRCC, HNSC, and LSCC are the cancer types where LPCAT1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LPCAT1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	IV	+1.741	<.001	12	view →
HNSC	Male	All	+0.908	<.001	12	view →
LSCC	Female	II,III,IV	−1.178	<.001	9	view →
COAD	Female	III,IV	+0.477	<.001	9	view →
PDAC	Female	II,III,IV	+0.841	<.001	8	view →
LUAD	All	All	+0.236	<.001	7	view →
OV	All	All	+0.299	.049	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

LPCAT1–CCRCC

Open the CCRCC breakdown →